Summary
This observational study examined clinical outcomes in patients with advanced urothelial cancer who received sequential anti-PD-1/PD-L1 immunotherapies. The authors evaluated efficacy and safety metrics in patients progressing from frontline to second-line checkpoint inhibitor treatment, as suggested by the journal scope and 2019 publication date in European Urology. The findings contribute to understanding of immune checkpoint inhibitor sequencing strategies in advanced urothelial malignancy.
UK applicability
This clinical oncology study addresses treatment sequencing for advanced urothelial cancer, which is relevant to UK oncology practice and National Institute for Health and Care Excellence (NICE) guidance on immunotherapy use. The findings may inform UK cancer treatment protocols, though applicability depends on NHS access to these therapies and UK patient populations.
Key measures
As suggested by the title: response rates, progression-free survival, overall survival, and adverse events following progression to second-line anti-PD-1/PD-L1 therapy
Outcomes reported
The study examined clinical outcomes in patients with advanced urothelial cancer who progressed through frontline and second-line anti-PD-1/PD-L1 checkpoint inhibitor therapies. Outcomes likely included response rates, overall survival, progression-free survival, and safety profiles across sequential immunotherapy lines.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.